Original Article
Journal of Perinatology (2008) 28, 511–517; doi:10.1038/jp.2008.28; published online 27 March 2008
Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry
M Frogel1, C Nerwen1, A Cohen2, P VanVeldhuisen3, M Harrington3 and M Boron2 for the Palivizumab Outcomes Registry Group
- 1Division of General Pediatrics, Schneider Children's Hospital, New Hyde Park, NY, USA
- 2Medical and Scientific Affairs, MedImmune, Gaithersburg, MD, USA
- 3The Synagis Outcomes Registry Coordinating Center, The EMMES Corporation, Rockville, MD, USA
Correspondence: Dr M Frogel, Division of General Pediatrics, Schneider Children's Hospital, 410 Lakeville Road, Suite 108, New Hyde Park, NY 11042, USA. E-mail: frogel@lij.edu
Received 31 August 2007; Revised 25 January 2008; Accepted 14 February 2008; Published online 27 March 2008.
Abstract
Objective:
The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Study Design:
Prospective observational registry enrolling those who received 
1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.
Result:
Of 19 548 subjects enrolled, 40% were born before 32 weeks', 48% between 32 and 35 weeks' and 12% after 35 weeks' gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
Conclusion:
Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.
Keywords:
bronchiolitis, palivizumab, pediatrics, prophylaxis, prematurity, respiratory syncytial virus
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Journal of Perinatology Original Article
Cost, causes and rates of rehospitalization of preterm infants
Journal of Perinatology Original Article
Cost, causes and rates of rehospitalization of preterm infants
Journal of Perinatology Original Article
The growth and potential of human antiviral monoclonal antibody therapeutics
Nature Biotechnology Research (01 Dec 2007)